Kips Bay Medical Announces Receipt of FDA Approval to Begin Clinical Study of the eSVS® Mesh in the United States

Published: Nov 08, 2012

MINNEAPOLIS--(BUSINESS WIRE)--Kips Bay Medical, Inc. (NASDAQ:KIPS) along with Manny Villafaña, its Founder, Chairman and CEO, announced today that the United States Food & Drug Administration (“FDA”) has granted approval with conditions of Kips Bay Medical’s Investigational Device Exemption (“IDE”) to include four U.S. study sites in the “eMESH I” clinical feasibility trial of its eSVS Mesh. As previously announced, this study commenced in Bern, Switzerland on August 31, 2012.

Back to news